Esperion Therapeutics, Inc. (ESPR) has a negative trailing P/E of -24.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 27.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.17%, forward earnings yield 3.60%. PEG 0.24 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.8 | -0.08 | 1.23 | 0.00 | - |
| 2017 | -9.4 | -0.09 | 6.44 | 0.00 | - |
| 2018 | -6.1 | -0.76 | -2.06 | 6.67 | - |
| 2019 | -16.6 | 0.36 | 80.97 | 10.89 | - |
| 2020 | -5.0 | -0.10 | -7.43 | 3.14 | - |
| 2021 | -0.5 | -0.01 | -0.73 | 1.84 | - |
| 2022 | -1.8 | 0.03 | -1.28 | 5.48 | - |
| 2023 | -1.5 | 0.03 | -0.68 | 2.65 | - |
| 2024 | -8.0 | 0.09 | -1.06 | 1.24 | - |
| 2025 | -33.9 | 0.56 | -2.55 | 1.91 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.33 | $0.00 | $-74.98M | - |
| 2017 | $-6.98 | $0.00 | $-166.99M | - |
| 2018 | $-7.54 | $184.47M | $-201.81M | -109.4% |
| 2019 | $-4.02 | $148.36M | $-109.02M | -73.5% |
| 2020 | $-6.05 | $227.55M | $-166.19M | -73% |
| 2021 | $-11.03 | $78.45M | $-318.82M | -406.4% |
| 2022 | $-4.33 | $75.48M | $-287.82M | -381.3% |
| 2023 | $-2.03 | $116.33M | $-209.25M | -179.9% |
| 2024 | $-0.28 | $332.31M | $-51.75M | -15.6% |
| 2025 | $-0.11 | $403.14M | $-22.68M | -5.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.07 | $-0.06 – $0.34 | $408.73M | $376.7M – $449.06M | 4 |
| 2027 | $0.05 | $0.05 – $0.06 | $444.71M | $391.75M – $481.5M | 3 |
| 2028 | $0.34 | $-0.53 – $0.99 | $553.23M | $546.35M – $560.11M | 4 |
| 2029 | $1.17 | $0.89 – $1.42 | $884.55M | $719.01M – $1.03B | 2 |
| 2030 | $1.67 | $1.26 – $2.03 | $1.12B | $911.85M – $1.31B | 2 |
